Skip to main content

Advertisement

Table 2 Prevalence of resistance to antiretroviral agents, Washington DC, 1999–2014

From: Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014

  Transmitted drug resistance
(n = 1503)
Acquired drug resistance
(n = 309)
Cumulative drug resistance
(n = 3411)
n % n % n %
NRTIsa
 Abacavir 52 3.5 59 19.1 826 24.2
 Didanosine 14 0.9 12 3.9 158 4.6
 Emtricitabine 47 3.1 63 20.4 828 24.3
 Lamivudine 47 3.1 63 20.4 828 24.3
 Stavudine 88 5.9 23 7.4 582 17.1
 Tenofovir 7 0.5 10 3.2 98 2.9
 Zidovudine 82 5.5 17 5.5 524 15.4
NNRTIsa
 Efavirenz 151 10.0 76 24.6 929 27.2
 Etravirine 19 1.3 11 3.6 212 6.2
 Nevirapine 153 10.2 74 23.9 926 27.1
 Rilpivirine 42 2.8 24 7.8 331 9.7
PIsb
 Atazanavir 27 1.8 10 3.2 181 5.3
 Darunavir 0 0.0 0 0.0 0 0.0
 Fosamprenavir 18 1.2 5 1.6 118 3.5
 Indinavir 17 1.1 2 0.6 175 5.1
 Lopinavir 22 1.5 4 1.3 166 4.9
 Nelfinavir 29 1.9 0 0.0 247 7.2
 Saquinavir 25 1.7 1 0.3 195 5.7
 Tipranavir 13 0.9 3 1.0 117 3.4
EIsa,c
 Enfuvirtide 17 1.1 3 1.0 52 1.5
INSTIsa
 Dolutegravir 0 0.0 0 0.0 4 0.1
 Elvitegravir 14 0.9 2 0.6 45 1.3
 Raltegravir 9 0.6 5 1.6 50 1.5
Any ARV 308 20.5 125 40.5 1538 45.1
Any NRTI 118 7.9 71 23.0 1013 29.7
Any NNRTI 176 11.7 81 26.2 998 29.3
Any PI 86 5.7 19 6.1 498 14.6
Any EI 17 1.1 3 1.0 52 1.5
Any INSTI 14 0.9 6 1.9 60 1.8
Any 2 classes 67 4.5 42 13.6 582 17.1
Any 3 classes 18 1.2 5 1.6 228 6.7
Any 4 classes 0 0.0 1 0.3 15 0.4
  1. NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; EI, entry/fusion inhibitor; INSTI, integrase strand transfer inhibitor
  2. aInterpreted using 2014 International Antiviral Society-USA (IAS) HIV-1 drug mutations classification
  3. bInterpreted using 2014 IAS classification and 2014 Stanford HIVDB genotypic resistance interpretation algorithm
  4. cThe 2014 IAS classification did not include maraviroc